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Background: The specific mechanism underlying the contribution of the Aldehyde dehydrogenase 1 (ALDH1)
phenotype to metastatic behavior and early tumor relapse in breast cancer is currently unclear.
Methods: 147 randomly selected invasive ductal carcinoma samples were assayed for expression of ALDH1A1,
NOTCH1, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2),
and association of the ALDH1A1 phenotype with clinic pathological features was further evaluated.
Results: ALDH1A1-positive cells were detected in 63.3% (93 of 147) of tumors. 80.0% (32 of 40) of tumors with
strong ALDH1A1 staining displayed early recurrence, compared with 20.0% (8 of 40) of tumors negative for
ALDH1A1 expression (P = 0.027). ALDH1A1 status was significantly correlated with strong malignant proliferative
marker Ki67 staining (P = 0.001), and no significantly different expression of ALDH1A1 across the subtypes of ER, PR,
and HER2 expression and triple negative features of tumor tissue. Multivariate regression analysis demonstrated that
elevated ALDH1A1 expression is an independent predictor of recurrence-free survival and distant metastasis-free
survival. Notably, breast cancer tissue strong for ALDH1A1 expression displayed weak NOTCH1 staining compared
to ALDH1A1 weak tumor tissue (P = 0.002), and the relationship between ALDH1A1 and NOTCH1 mRNA positivity
was significant (Pearson correlation - 0.337, P = 0.014; Spearman’s rho - 0.376, P = 0.006). Elevated NOTCH1 mRNA
level (using a cut-off value based on the median ALDH1A1 2-△△CT value) was associated with reduction of ALDH1A1
mRNA level (P = 0.001).
Conclusions: The ALDH1A1 phenotype is an independent predictor of early tumor relapse characteristic
(specifically, incidence of early local recurrence and distant metastasis) of invasive ductal carcinoma. The NOTCH1
signaling pathway is possibly involved in the negative association of the ALDH1A1 phenotype with early malignant
relapse in invasive ductal carcinoma.
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Breast invasive ductal carcinoma is a common breast ma-
lignancy and a major cause of cancer-related death in
women worldwide [1]. Despite developments in surgical
methods, cytotoxic chemotherapy, and targeting agents
against estrogen receptor and HER2, a subset of patients
with advanced-stage invasive ductal carcinoma display
poor prognosis and early metastasis after single or* Correspondence: pumclinyan@163.com
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reproduction in any medium, provided the orcombination treatment. An estimated 11% of women with
invasive ductal carcinoma will experience recurrence
within five years after surgery, including 8% with luminal A
breast cancers and 15% with triple negative tumors [2,3].
The cancer stem cell hypothesis was proposed to explain
breast cancer heterogeneity and risk of recurrence. These
cell subpopulations have the capacity to self-renew and dif-
ferentiate into multiple cell types, and may contribute to
drug resistance that promotes tumor recurrence or metas-
tasis [4]. Several cellular subcomponent changes have beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ase 1 (ALDH1) positivity, CD44 positivity, CD24 negativity,
RHOC overexpression, hypomethylation of caveolin pro-
moters, and deletion of some tumor suppressors [5-9].
Among these molecules, ALDH1, an enzyme responsible
for the oxidation of intracellular aldehydes, has been a
subject of research focus in recent years [9,10]. Several
studies have suggested that ALDH1 contributes to normal
and tumor stem cell differentiation, and invasion and me-
tastasis in breast cancer are mediated by a cellular
subcomponent with stem cell characteristics expressing
ALDH1 [11,12]. For example, populations of normal
mammary epithelial cells with increased ALDH1 activity
have the ability to form mammospheres and self-renew,
and breast carcinoma cells with high ALDH1 activity dis-
play tumor-generating potential. These findings indicate
that the breast carcinoma cells with ALDH1 phenotype
participate in the acquisition of progenitor features [9,13].
In addition, emerging evidence suggests that ALDH1 plays
important functional roles related to self-protection [14].
Another previous report describing the association of
ALDH1 expression with early metastasis and decreased
survival in inflammatory breast cancer has further demon-
strated a critical role of ALDH1-positive cancer cells in
mediating the clinically aggressive behavior of breast can-
cer [15]. However, the mechanisms by which the ALDH1
phenotype contributes to malignant cell metastatic behav-
ior, such as early tumor relapse, distant recurrence, self-
renewal, and proliferation in breast cancer are yet to be
established.
In terms of regulation of cellular proliferation and dif-
ferentiation, several known signaling pathways, such as
NOTCH, play a role in self-renewal of stem cells [16,17].
Previously, up regulation of NOTCH ligands led to ele-
vation of the mammosphere number, and conversely,
down regulation abrogated mammosphere formation,
providing evidence that the NOTCH signal pathway
contributes to mammary gland development [18]. On
the other hand, although overexpression of NOTCH li-
gands in a transgenic mouse model triggered breast can-
cer, supporting the theory that NOTCH contributes to
cancer development [19,20], the finding that NOTCH
signaling is diminished in some solid tumors would
seem to suggest that NOTCH might serve as a tumor
suppressor [21,22]. However, no evidence of an associ-
ation of the NOTCH signaling pathway with prolifera-
tion or suppression of the ALDH1-expressing cellular
subcomponent displaying early tumor relapse character-
istics has been obtained to date.
In the current study, we primarily investigated
whether breast cancer cells with the ALDH1 phenotype
contribute to early malignant relapse behavior, and
further discussed the possible underlying biological
mechanisms.Materials and methods
Patients and specimens
In total, 147 invasive ductal carcinoma samples were ran-
domly selected from our tissue database of patients treated
at the Peking Union Medical College Hospital between
April 2000 and December 2007. None of the patients had
received neoadjuvant chemotherapy or radiotherapy. Clin-
ical information was obtained by reviewing preoperative
and perioperative medical records, follow-up records, and
written correspondence. Patients were staged based on
tumor-node-metastasis (TNM) classification of the Inter-
national Union Against Cancer, revised in 2002 [23]. The
clinical characteristics of patients are shown in Table 1.
Fresh-frozen tumor tissue samples were used for routine
examination of the estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor recep-
tor (HER) 2. Paraffin specimens of these tumors were col-
lected, and 5 mm-thick tissue sections cut and fixed onto
silicified slides. Each sample was stained with hematoxylin
and eosin (H&E), and histologically typed according to the
World Health Organization (WHO) classification system
[24]. Tumor sizes, and the number and location of meta-
static lymph nodes were obtained from pathology reports.
The use of human materials was approved by the Peking
Union Medical College Hospital Medical Ethics Commit-
tee (Full name of the board/committee: Peking Union
Medical College Hospital Medical Ethics Committee. No.
S-294). We confirm that written informed consent from
the donor or the next of kin was obtained for use of this
sample in research.
Immunohistochemical staining and evaluation
Briefly, individual tissue sections were deparaffinized,
rehydrated and incubated with fresh 3% hydrogen peroxide
(H2O2) in methanol for 15 min. After rinsing with
phosphate-buffered saline (PBS), samples were immersed
in 0.01 M sodium citrate buffer (pH 6.0) and heated in a
microwave oven at 100 °C for 15 min for antigen retrieval.
Non-specific binding was blocked by incubating the sec-
tions with normal goat serum for 15 min at room
temperature. Samples were subsequently incubated at 4°C
overnight with different primary antibodies, including
rabbit monoclonal to ALDH1 (ALDH1A1, IgG, 1:100,
Abcam, Cambridge, UK), rabbit polyclonal to NOTCH1
(NOTCH1, IgG, 1:100, Abcam, Cambridge, UK), FITC-
linked mouse monoclonal to SABC (1:50), and goat
anti-rabbit Cy3 antibody (IgG, 1:20). ALDH1 and
NOTCH1 expression were detected using a Nikon Eclipse
80i microscope and the Mcv2000 Image Analysis System.
All slides were counterstained with hematoxylin to identify
nuclei. Samples were scored twice by one individual in a
blinded fashion, and unclear findings were further
discussed with a pathologist. In cases of staining discrepan-
cies among the three cores from the same patient, an
Table 1 Association of ALDH1 expression with clinical and pathologic factors in breast cancer tissues (χ2 test)
n
ALDH1A1 expression P
value– + ++ +++
Age (years) 147 52.2 ± 11.9 51.6 ± 13.0 53.2 ± 13.0 48.5 ± 12.7 0.682
Tumor size (cm) 147 3.9 ± 0.6 2.6 ± 0.2 2.9 ± 0.6 3.9 ± 0.5 0.103
Lymph node involvement 115 45 (39.1%) 45 (39.1%) 9 (4.0%) 16 (13.9%) 0.389
TNM stages
I 14 4 (28.6%) 8 (57.1%) 1 (7.1%) 1 (7.1%) 0.177
II 56 19 (33.9%) 25 (44.6%) 6 (10.7%) 6 (10.7%)
III 76 31 (40.8%) 29 (38.2%) 5 (6.6%) 11 (14.5%)
IV 1 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (100.0%)
NOTCH1 expression
– 9 7 (77.8%) 2 (22.2%) 0 (0.0%) 0 (0.0%) 0.044
+ 26 7 (26.9%) 17 (65.4%) 2 (7.7%) 0 (0.0%)
++ 24 10 (41.7%) 8 (33.3%) 1 (4.2%) 5 (20.8%)
+++ 88 30 (34.1%) 36 (40.9%) 8 (9.1%) 14 (15.9%)
Ki67 expression
– 79 38 (48.1%) 35 (44.3%) 6 (7.6%) 0 (0.0%) 0.001
+ 68 16 (23.5%) 28 (41.2%) 5 (7.4%) 19 (27.9%)
P53 expression
– 100 35 (35.0%) 45 (45.0%) 8 (8.0%) 12 (12.0%) 0.823
+ 47 19 (40.4%) 18 (38.3%) 3 (6.4%) 7 (14.9%)
ER expression
– 90 34 (37.8%) 35 (38.9%) 6 (6.7%) 15 (16.7%) 0.303
+ 57 20 (35.1%) 28 (47.4%) 5 (8.8%) 4 (7.0%)
PR expression
– 83 27 (32.5%) 38 (45.8%) 5 (6.0%) 13 (15.7%) 0.400
+ 64 27 (42.2%) 25 (39.1%) 6 (9.4%) 6 (9.4%)
HER2 expression
– 77 32 (41.6%) 32 (41.6%) 4 (5.2%) 9 (11.7%) 0.492
+ 70 22 (31.4%) 31 (44.3%) 7 (10.0%) 10 (14.3%)
Triple negativity features*
– 108 40 (37.0%) 44 (40.7%) 10 (9.3%) 14 (13.0%) 0.541
+ 39 14 (35.9%) 19 (48.7%) 1 (2.6%) 5 (12.8%)
Local recurrence
Present 40 8 (20.0%) 20 (50.0%) 6 (15.0%) 6 (15.0%) 0.027
Absent 107 46 (43.0%) 43(40.2%) 5 (4.7%) 13 (12.1%)
Distant metastasis
Present 51 21 (41.1%) 20 (39.2%) 3 (5.9%) 7 (13.7%) 0.809
Absent 96 33 (34.3%) 43 (44.8%) 8 (8.3%) 12 (12.5%)
ALDH aldehyde dehydrogenase, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2.
* Immunohistochemically negative for ER, PR, and HER2.
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were detected mainly in the cytoplasm.
Real-time PCR
Total RNA was obtained using the RNAqueous-Micro kit
(Ambion, Austin, TX, USA), following the manufacturer’sinstructions. Power SYBR Green PCR Master Mix (Applied
Biosystems) was employed to amplify the corresponding
genes with primers specific for human NOTCH 1 (forward:
5'-GACCTCATCAACTCACACGC-3', reverse: 5'-CGGCA
TCCACATTGTTCA-3'). Human GAPDH (Hs_GAPD
H_2_SG QuantiTect Primer Assay QT01192646, Qiagen,
Figure 1 Immunohistochemical analysis of ALDH1A1 and
NOTCH1 expression in invasive ductal carcinoma samples.
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time PCR was performed on a Linegene Real-time PCR de-
tection system (Bioer Technology, China). Data were
analyzed using the 2-△△CT method [25].
Statistical analysis
All calculations were performed using SPSS V.14.0 statis-
tical software (Chicago, IL, USA). T-test, Mann–Whitney
U test, and Fisher’s exact test were applied where appropri-
ate. The Kaplan-Meier method was used to estimate
cumulative recurrence-free survival (RFS) and metastasis-
free survival (MFS), and the log-rank test to compare
survival between two strata, respectively. All tests were




The baseline characteristics of the study population are
presented in Table 1. All patients were female, with a mean
age of 51.6 ± 12.5 years (range, 13.5 to 80.7 years) and
mean tumor size of 3.1 ± 1.8 cm (range, 0.4 to 9.5 cm).
Lymph node involvement was positive in 115 patients
(78.2%). According to the TNM staging system, 14 patients
(9.5%) were classified as stage I, 56 (38.1%) as stage II, 76
(51.7%) as stage III, and 1 (0.7%) as stage IV. Among the
147 patients, 57 (38.8%) were positive for ER, 64 (43.5%)
for PR, 70 (47.6%) for HER2, and 39 (26.5%) for triple
negativity features (defined as immunohistochemically
negative for both SR and HER2). Median follow-up time
was 23.0 months (range, 2 to 91 months), during which
27.2% patients (40 of 147) experienced tumor recurrence
and 34.7% (51 of 147) developed metastases.
Presence of the ALDH1A1 phenotype in invasive ductal
carcinoma tissue
Immunohistological analysis of serial tumor sections re-
vealed ALDH1A1 positivity in cells from invasive ductal
carcinoma tissues, as illustrated by strong cytoplasmic
staining (Figure 1). ALDH1A1-positive cells were detected
in 63.3% (93 of 147) of tumors, with 42.9% (63 of 147)
showing slight staining, 7.5% (11 of 147) moderate staining,
and 12.9% (19 of 147) strong staining. Furthermore, in the
follow-up period, 80.0% (32 of 40) of tumors with positive
ALDH1A1 expression displayed recurrence, compared
with 20.0% (8 of 40) of ALDH1A1-negative tumors
(P = 0.027). ALDHA1-negative cells were mainly observed
in the cases without local recurrence (43.0%, 46/107 cases).
On the other hand, no linkage was observed between
ALDH1A1 phenotype and postoperative metastasis. More-
over, we observed no stepwise increase in the prevalence of
ALDH1A1 expression with TNM stage, lymph node in-
volvement, ER, PR, and HER2 expression and triple nega-
tivity features of invasive ductal carcinoma tissue, itdemonstrated that no significantly different expression of
ALDH1 across these subtypes in invasive ductal carcinoma
(Table 1).
Association of the ALDH1A1 phenotype with RFS and MFS
Local recurrence-free survival differed significantly be-
tween ALDH1A1 subtypes. Median RFS in ALDH1A1
positive tumors was 28.1 months (95% CI: 24.8–31.4)
compared with 49.3 months (95% CI: 45.8–52.7) in
ALDH1A1 negative tumors (P = 0.001, Figure 2A). Mean-
while, distant metastasis-free survival also showed prom-
inent difference between ALDH1A1 subtypes. Median
MFS in ALDH1A1 positive tumorscpe was 27.7 months
(95% CI: 25.0–30.5) compared with 43.2 months (95% CI:
39.2–47.2) in ALDH1A1 negative tumors (P = 0.001,
Figure 2B). Our data demonstrated that positive
ALDH1A1 phenotype was significantly associated with
RFS and MFS. Notably, multivariate Cox proportional haz-
ards regression analysis implied that elevated ALDH1A1
expression in invasive ductal carcinoma is an independent
predictor of recurrence-free survival and also distant
metastasis-free survival (Tables 2 and 3). Therefore, the
ALDH1A1 phenotype is an independent predictor of early
tumor relapse characteristic (specifically, incidence of local
recurrence and distant metastasis) of invasive ductal
carcinoma.
Association of the ALDH1A1 phenotype with proliferative
features
Among the 147 samples with available data on Ki67, one
of the malignant proliferative indices, 51.9% (41 of 79)
cases with negative Ki67 expression and 76.5% (52 of 68)
with positive Ki67 expression were positive for the
ALDH1A1 phenotype, respectively. ALDH1 status was
significantly correlated with strong Ki67 staining in all
Figure 2 Analysis of recurrence-free survival (RFS, A) and distant metastasis-free survival (MFS, B) in breast cancer patients with and
without the ALDH1 phenotype.
Table 2 Univariate and multivariate analysis of ALDH1A1 phenotype in relation to recurrence-free survival (RFS)
Variable
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
ALDH1A1
Positive 11.932 4.190–33.977 0.001 11.399 3.776–34.414 0.001
Negative 1.000 1.000
ER status
Positive 1.013 0.519–1.977 0.970 1.579 0.636–3.921 0.325
Negative 1.000 1.000
PR status
Positive 0.669 0.345–1.299 0.235 0.568 0.238–1.358 0.203
Negative 1.000 1.000
HER2 status
Positive 1.307 0.701–2.435 0.400 1.564 0.599–4.085 0.361
Negative 1.000 1.000
Triple negativity features*
Present 0.848 0.441–1.631 0.620 0.808 0.241–2.702 0.729
Absent 1.000 1.000
TNM stage
Stage III/IV 0.718 0.373–1.382 0.321 0.803 0.402–1.601 0.532
Stage I/II 1.000 1.000
Age (years)
≥ 50 0.709 0.376–1.338 0.289 0.803 0.402–1.601 0.532
< 50 1.000 1.000
Abbreviations: HR hazard ratio estimated from Cox proportional hazard regression model, CI confidence interval of the estimated HR, ER estrogen receptor,
PR progesterone receptor, HER2 human epidermal growth factor receptor 2.
*Immunohistochemically negative for ER, PR, and HER2.
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Table 3 Univariate and multivariate analysis of ALDH1A1 phenotype in relation to distant metastasis-free survival
(MFS)
Variable
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
ALDH1A1
Positive 3.501 1.785–6.866 0.001 3.562 1.790–7.091 0.001
Negative 1.000 1.000
ER status
Positive 1.111 0.614–2.012 0.727 1.510 0.693–3.290 0.300
Negative 1.000 1.000
PR status
Positive 0.956 0.546–1.674 0.875 1.052 0.479–2.310 0.900
Negative 1.000 1.000
HER2 status
Positive 0.969 0.554–1.694 0.911 1.161 0. 540–2.495 0.703
Negative 1.000 1.000
Triple negativity features*
Present 0.870 0.481–1.573 0.645 0.741 0.265–2.073 0.569
Absent 1.000 1.000
TNM stage
Stage III / IV 1.874 1.010–3.475 0.046 2.248 1.173–4.307 0.015
Stage I / II 1.000 1.000
Age (years)
≥ 50 1.399 0.793–2.467 0.247 1.585 0.846–2.970 0.151
< 50 1.000 1.000
Abbreviations: HR hazard ratio estimated from Cox proportional hazard regression model, CI Confidence interval of estimated HR. ER estrogen receptor, PR
progesterone receptor; HER2 human epidermal growth factor receptor 2.
*Immunohistochemically negative for ER, PR, and HER2.
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ALDH1A1 phenotype with malignant proliferation in in-
vasive ductal carcinoma.
Association of the ALDH1A1 phenotype with NOTCH1 mRNA
In immunohistochemical experiments, we observed a step-
wise decrease in the prevalence of ALDH1A1 expression
with NOTCH1 status (P = 0.044) (Table 1, Figure 1).
ALDH1A1-negative breast cancer tissue displayed strong
NOTCH1 staining (1.92 ± 0.37), compared to ALDH1A1-Table 4 Measurement of ALDH1A1 and NOTCH1 mRNA with r
Target ALDH1A1
n 52
Avg. CT 22.55 ± 1.21 (19.25~25.07)
△CT −1.03 ± 0.21 (− 4.33~1.49) −
△△CT 0.08 ± 0.01 (− 2.56~4.37)
2-△△CT 1.75 ± 0.70 (0.05~5.88)
a Total RNA was purchased from Clontech, and cDNA synthesized from 1 mg total R
for real-time PCR reactions containing either primers and probe for ALDH1A1 or NO
total RNA, and six replicates per reaction were performed.positive breast cancer tissue (0.61 ± 0.11, P = 0.002). Real-
time PCR experiments revealed a significant relationship
between ALDH1A1 and NOTCH1 mRNA in 52 samples
(Pearson correlation - 0.337, P = 0.014; Spearman’s rho -
0.376, P = 0.006, Table 4). It seemed many high ALDH1A1
mRNA samples showed weak NOTCH1 mRNA level, and
moderate or high expression of NOTCH1 was parallel to
the absence or little expression of ALDH1 expression
(Figure 3E). Elevated NOTCH1 mRNA level (using a cut-
off value based on the median ALDH1A1 2-△△CT value)eal-time PCRa
NOTCH1 β-actin
52 52
28.12 ± 1.65 (24.62~31.76) 18.19 ± 2.16 (14.63~22.80)
0.50 ± 0.65 (− 4.01~3.14) −1.11 ± 0.16 (− 4.67~3.50)
0.61 ± 0.03 (− 2.85~4.49)
1.29 ± 0.58 (0.04~7.19)
NA using reverse transcriptase. Aliquots of cDNA were used as the template
TCH1 and probe for β-actin. Each reaction included cDNA derived from 10 ng
Figure 3 Results of real-time PCR. A. Amplified curve analysis of actin. B. Melting curve analysis of actin. C. Amplified curve analysis of NOTCH1.
D. Melting curve analysis of NOTCH1. E. Compare of 2-△△CT value of ALDH1A1 and NOTCH1 expression in each case. F. Compare of mean 2-△△CT
value of NOTCH1 expression regarding to ALDH1A1 expression (using a cut-off value based on the median ALDH1A1 2-△△CT value).
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(P = 0.001, Figure 3F). Our findings collectively suggest a
possible negative association of the ALDH1A1 phenotype
with NOTCH1 in invasive ductal carcinoma.Discussion
The important properties of cancer stem-like cells include
in vitro self-renewal, in vivo tumor initiation, and generat-
ing a heterogeneous population of cancer cells. Prolifera-
tion is an important characteristic in tumor biology.
ALDH1-positive cancer cells are highly clonogenic and
tumorigenic in vitro, and suppression of ALDH1 leads to
lower tumorigenicity. Moreover, dissociated cells of en-
graftments created from ALDH1A1-positive cancer cells
present an average of 29% ALDH1A1-negative cancer cells,
indicating that the ALDH1 phenotype gives rise to hetero-
geneous tumors. Although ALDH1-positive breast cancer
cells are believed to be directly responsible for cancer cell
growth in vitro, the association of the ALDH1 phenotype
with tumor cell proliferation in vivo has not been evaluated
until now.
In the present study, positive ALDH1A1 expression
was observed in 63.0% (92 of 146) of human invasiveductal carcinoma tissues (including slight, moderate, and
strong staining), and the incidence of moderate or strong
staining were 21.4%. Our observed percentage of cancer
samples positive for ALDH1A1 was consistent with find-
ings in other types of prostate, head-and-neck solid
malignancies, but higher than the subpopulations of
ALDH1A1-positive cells in bladder and lung tumors
[26-29]. Earlier studies have reported increased ALDH1A1
expression in 30% of breast tumor specimens and 34% of
inflammatory breast carcinomas [13,15], while a recent re-
port showed the presence of epithelial ALDH1 and ex-
panded stromal ALDH1-positive cells in 43% and 69% of
breast tumor biopsies, respectively [30]. These differences
among the studies may be attributed to the diversity of de-
tection techniques and samples under investigation, espe-
cially since all the cases examined in our study were
invasive ductal carcinoma. The data provides further evi-
dence of enrichment of ALDH1-positive cancer cells in
invasive ductal carcinoma tissue.
Clinical description of the ALDH1 phenotype in tumor
cells is interesting. While elevated ALDH1A1 expression
in tumor cells is reported to correlate with advanced
tumor grade and stage in bladder and lung cancer, and
patients with the ALDH1 phenotype in tumors display
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cell ALDH1 expression is significantly correlated specif-
ically with triple negativity features or HER2 tumor types
in the adjuvant series and tumor grade in the neoadjuvant
cohort, and no significant enrichment for ALDH1 positive
cells has been observed in postneoadjuvant therapy speci-
mens, compared to pretreatment samples [30,31]. These
findings suggest that the tumor microenvironment plays a
role in determining the prognostic impact of stem/pro-
genitor cells in human breast cancer [32]. Moreover, our
data revealed no association of the ALDH1 phenotype
with age, TNM stage, tumor size, or lymph node involve-
ment. Surprisingly, the association of ALDH1 expression
in breast cancer cells with early local recurrence affair
seemed practically different with the linkage between
ALDH1 phenotype and metastatic event. We observed a
significant positive relationship between ALDH1 pheno-
type and early local recurrence affair in the patients, indi-
cating that ALDH1-positive cases have an enlarged cancer
stem cell component.
Based on our finding that cases with early local recur-
rence and distant metastasis show significantly more fre-
quent epithelial ALDH1 expression, association of the
ALDH1 phenotype in breast cancer with tumor cell prolif-
eration was further evaluated in the present study. The re-
sults disclosed a positive relationship between ALDH1
phenotype and Ki67 in invasive ductal carcinoma speci-
mens. Since the Ki67 protein is present during active
phases of the cell cycle, our data suggest that the ALDH1
phenotype in tumor cells may be associated with cell prolif-
eration. On the other hand, we observed no association be-
tween phenotypes of P53, indicative of apoptosis, and
ALDH1 in invasive ductal carcinoma specimens. Thus, it
appears that ALDH1 does not contribute to tumor apop-
tosis. Given the association between high ALDH1 expres-
sion and elevated staining for the proliferating cell marker,
we focused on whether ALDH1 is linked to the cell prolif-
eration pathway. Both immunohistochemistry and real-
time PCR experiments demonstrated a strong association
of ALDH1 with the reversed NOTCH1 expression in breast
cancer. Although several studies showed that NOTCH fam-
ily member levels were elevated in various breast tumor
samples and cell lines and upregulation of specific NOTCH
proteins would lead to increased tumor cell proliferation
and invasion [33-35], our findings demonstrated that mod-
erate or high expression of NOTCH1 was parallel to the
absence or little expression of ALDH1 expression and this
inconsistency seemed NOTCH signaling pathway may
played a negative role on ALDH1-positive breast cancer
cells, which was similarly with the finding that NOTCH sig-
naling might serve as a tumor suppressor in some solid tu-
mors [21,22]. Thus, clinical benefits by regulation of
NOTCH potentially in targeting ALDH1-positive breast
cancer cells may be a complex question worth researching.Although we speculate that ALDH1 in invasive
ductal carcinoma tissue contributes to tumor cells pro-
liferation, other aspects involved in metastasis, such as
drug resistance, tumor metabolism, angiogenesis, and
lymphangiogenesis, have not been directly investigated
to date. Notably, high ALDH1-expressing breast cancer
cells survived chemotherapy/radiotherapy, relative to
cells expressing low levels of ALDH1, and pre-
treatment of cell populations with the ALDH inhibitor,
diethylaminobenzaldehyde, resulted in significant ini-
tial sensitization of ALDH-expressing cells to chemo-
therapy or radiotherapy. These findings indicate that
the ALDH1 phenotype contributes to both chemother-
apy and radiation resistance in breast cancer [32].
More importantly, in addition to the epithelial ALDH1
phenotype, stromal ALDH1 may be associated with
breast cancer development [30]. While the biological
function of the ALDH1 phenotype in breast cancer has
been established, the mechanisms by which ALDH1 in-
tegrates its activity to control specific events remain to
be clarified. Moreover, we are yet to determine whether
modulation of such a pleiotropic pathway can serve as
a potential therapeutic target in breast cancer therapy
and regenerative medicine.
Conclusions
We observed variations in the prevalence of ALDH1-
expressing tumor cells among different subtypes of invasive
ductal carcinoma. Our findings demonstrate that the cellu-
lar subcomponent with stem cell characteristics expressing
ALDH1 contributes to early tumor replase behavior, pos-
sibly in association with the NOTCH signaling pathway. In
conclusion, the current study has highlighted the import-
ance of the ALDH1 status in translating cancer stem cell
research into clinical practice, and further identified
ALDH1 as a potential therapeutic target in invasive ductal
carcinoma.
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